Healio - Viekira Pak safe for patients with HCV, Child-Pugh A cirrhosis

New In Hepatology At Healio

October 5, 2017

Viekira Pak safe for patients with HCV, Child-Pugh A cirrhosis
Poordad F, et al. J Hepatol. 2017;doi:10.1016/j.jhep.2017.06.011.

Patients with hepatitis C and Child-Pugh A cirrhosis had similar rates of treatment-related adverse events and lower rates of hepatic decompensation after treatment with Viekira Pak compared with untreated patients, according to recently published data. However, those with a history of advanced cirrhosis were more likely to experience treatment-related adverse events.

Read More - https://www.healio.com/hepatology/hepatitis-c/news/online/%7Be4ff72dc-3ade-4e42-b1bb-83109f95e69f%7D/viekira-pak-safe-for-patients-with-hcv-child-pugh-a-cirrhosis

Study - Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis
Published in The Journal of Hepatology
October 2017 Volume 67, Issue 4, Pages 700–707

Liver cancer remains a leading cause of cancer-related mortality worldwide

Primary liver cancer incidence increased by 75% between 1990 and 2015, and the disease remains one of the leading causes of cancer death in the world, according to a report from the Global Burden of Diseases Study 2015. Further, hepatitis B virus was the leading cause of new cases of liver cancer in 2015, the research showed.

In Case You Missed It

Oct 4, 2017

AASLD, IDSA update HCV guidance for resistance, new drug approvals

The AASLD and the Infectious Diseases Society of America have updated their guidelines and resources for the diagnosis and treatment of hepatitis C virus infection…

Despite treatment, severe steatosis predicts severe fibrosis in HBV
Severe steatosis correlated with severe fibrosis in patients with chronic hepatitis B, whether patients were on treatment or treatment-naive, according to recently…

Free registration may be required